

幹細胞新藥的領航者

A Pioneer of Stem Cell Medicine Development

Gwo Xi Stem Cell Applied Technology Co., Ltd., (Stock Code: 6704-TW) has established pharmaceutical grade stem cell preparation platform since 2011. The platform established across the entire cell therapy industry chain have developed 4 stem cell medicines certified by TFDA and two of them are going forward to clinical trial phase III.




GWOXI Stem Cell Medicines



- Autologous ADSCs / Indication: Liver Cirrhosis
- In the human trial, GXHPC1 has been proved that it can ameliorate hepatic inflammation and reverse fibrosis area 6 months after transplantation.











Source: Cell Transplantation. 2019;1-12.

Autologous ADSCs / Indication: Chronic Stroke

 In the human trial, GXNPC1 has demonstrated that it did not cause SAE and the brain infarction area drastically reduced in all subjects 6 months after transplantation.



(NCT02813512) Source: J Tissue Eng Regen Med. 2021;1-11.

思益優 GXNPC1

6 months Post-injection Pre-injection












Knee OA

Liver Fibrosis










Allogeneic ADSCs / Indication: Knee Osteoarthritis

Health Knee Joint

In the human trial, GXCPC1 has demonstrated that it can relieve pain and improve physical function and stiffness of the joint in WOMAC Score.



*, #: Sign of significant difference in the high-dose cohort and low-dose cohort, respectively

Source: Cell Transplantation. 2023;33:1-10.

- Allogeneic ADSCs / Indication: Diabetes
- In the pre-clinical research results, GXIPC1 showed therapeutic potential in regulating blood sugar and protecting islets.

Pre-Clinical Results:

